Drug Trial Radar · NCT00830674
A Study of KRN23 in X-linked Hypophosphatemia
Last checked: Nov 20, 2026Latest source record: Jun 17, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
42
Actual
Start
Dec 2008
Primary completion
Dec 2011
Study completion May 2013
Sponsor
- Lead sponsor
- Kyowa Kirin Co., Ltd.Industry
- Sponsor type
- Industry
- Collaborators
- Kyowa Hakko Kirin Pharma, Inc.
- First posted
- Jan 28, 2009
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to assess the safety and tolerability of KRN23 after a single intravenous (IV) and subcutaneous (SC) administration in XLH patients.
Conditions
- X-linked Hypophosphatemia
Interventions
PlaceboDrug
single dose IV or SC administration
KRN23Drug
Single IV administration on day 1: 0.003, 0.01, 0.03, 0.1 and 0.3 mg/kg and Single SC administration on day 1: 0.1, 0.3, 0.6 and 1.0 mg/kg
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and tolerabilityTime frame: Up to 7 weeks after dosing (maximally 11 weeks)
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Yale University School of Medicine
New Haven, Connecticut
General Clinical Research Center, Indiana University School of Medicine
Indianapolis, Indiana
Duke Clinical Research Unit
Durham, North Carolina
University of Texas Health Science Center at Houston
Houston, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.